Intermediate frequency and low intensity static electric field have been developed for non-invasive cancer therapy nowadays. The evaluation of the vital organs, one of which is kidney and liver, is necessary for pre-clinical safety assessment. This research aimed to evaluate the effect of the intermediate frequency (150 kHz) and low intensity (18 Vpp) static electric fields in kidney tissue of rats induced by DMBA (7,12-Dimethylbenz [α] anthracene). This study was carried out in breast tumor models using Sprague Dawley (SD) rats induced with 7,12-Dimethylbenz [α] anthracene (DMBA) by 20 mg/kg body weight of dose ten times over five weeks. Twenty-four rats were divided into four groups, namely: Non-induction Non-therapy (NINT), Non-Induction Therapy (NIT), Induction Non-Therapy (INT), and Induction Therapy (IT) groups. Static electric field therapy is carried out for 10 hours (resting 2 hours after 5 hours exposure) per day using the Electro-Capacitive Cancer Therapy (ECCT) individual enclosure for 21 days. The blood samples were collected before and after therapy for AST, ALT, and Creatinine measurement. The samples of liver and kidney were processed using Paraffin Method and Hematoxylin-Eosin Staining for histopathological observation. The histopathological score was determined using the ordinal method and post-examination masking. This study reveals that the 150 kHz and 18 Vpp static electric field therapy doesn’t significantly induce histopathological injuries on the liver and the kidney. Furthermore, it also does not have a negative impact on the creatinine, AST, and ALT levels of blood plasma.